Co-Founder – Icon Group, Chairman – Icon Asia and Chairman – Icon Group
Stuart Giles was the Founding Chairman and driving force behind the establishment of Icon Cancer Care. He remains a significant investor in Icon Group and has played an active role at a Board level, with a strong focus on driving international growth in recent years. His role as Chairman of Icon Asia involves leading the Group’s development throughout South-East Asia, including the Icon SOC [Singapore Oncology Consultants] clinics in Singapore, as well as the Group’s growth into China. Following the recent acceptance of a $1.1bn offer from an investor consortium led by QIC and anchored by Goldman Sachs PIA in Hong Kong, Stuart has accepted the role of company Chairman.
Anyone who’s met Stuart knows he brings an energetic and innovative approach to developing commercial success and expanding the boundaries of healthcare. He’s been publicly recognised for his commercial expertise in forums including the 2010 Ernst and Young Entrepreneur of the Year where he was named a Regional Winner and National Finalist.
A pharmacist by background, Stuart and his wife, Cathie Reid, own and operate a network of Epic pharmacies around Australia, to which Icon Group provides management services.
Stuart is passionate about contributing to the community and served on the Board of Directors for the AEIOU Foundation for Children with Autism. He supported medical research as a Founding Platinum sponsor of the Gallipoli Research Foundation, before he and Cathie launched the Epic Good Foundation in 2015.
Stephanie is head of the Merchant Banking Division (MBD) in Asia Pacific Ex-Japan. She serves on the Partnership Committee, Asia Pacific Management Committee, MBD Corporate Investment Committee and Asia Pacific Diversity Committee. Stephanie initially joined Goldman Sachs in 1995 as a financial analyst. She worked in the Principal Investment Area in New York and then transferred to Hong Kong in 1997. Stephanie left Goldman Sachs in 1998 to attend graduate school, rejoined the firm as an associate in 2000 and became an executive director in 2003. She was named managing director in 2006 and partner in 2010.
She serves on the Investment Committee of Hony Capital Fund III and Hony Capital Fund 2008. Stephanie is also a member of the Board of Governors of the China Venture Capital and Private Equity Association, the Board of Directors of Save the Children Hong Kong and Honorary Trustees of The Women’s Foundation.
Stephanie earned an AB in Biology, summa cum laude, from Harvard College in 1995 and an MBA from Harvard Business School in 2000.
James is Chairman and managing partner at Pagoda Investment. He has more than 25 years of private equity investment and asset management experience. Before founding Pagoda Investment, he was a senior executive at CIC, China’s Sovereign Wealth Fund. He’s also a senior advisor to QIC. Pagoda Investment is a private equity fund focusing on innovative technology, health science and advance manufacturing.
James holds a Bachelor in Economics and Finance from RMIT university and Master in Applied Finance from Macquarie University, Australia.
Dr Ian Irving brings strong leadership to the board having performed senior clinical and administrative roles in the cancer care sector and is currently Medical Director of Icon Cancer Care. Ian spent several years in haematology practice at Icon Townsville, and during that time was also the Director of Haematology and Bone Marrow Transplantation at the Townsville Hospital and the Clinical Director of the Institute of Cancer from 2006 – 2013. He was also responsible for consolidating and expanding tertiary level cancer care in North Queensland. He continues his practice at Icon Cancer Care Wesley.
Further to his broad haematological knowledge, Ian has a special clinical interest in lymphoma, myelodysplasia and myeloproliferative disorders. He has sat on national and international committees and advisory boards, focusing on haematological disorders such as chronic myeloid leukaemia, myelofibrosis, myelodysplasia, lymphoma and bone marrow transplantation. Ian is a strong advocate for clinical trial research, participating in phase I, II and III multi-centre clinical trials.
Tim is a member of the corporate investing team in the Merchant Banking Division at Goldman Sachs, responsible for making and managing private equity investments in Asia Ex-Japan. He focuses on investments in financial institutions, consumer and retail as well as health care sectors. Tim joined Goldman Sachs as an associate in 2006. He was promoted to managing director in 2012 and named partner in 2016.
Prior to joining the firm, Tim worked at Deutsche Bank’s Health Care Group in Baltimore and Financial Institutions Group in Hong Kong.
Tim earned a BS in Economics with a concentration in Finance from the Wharton School of the University of Pennsylvania in 2001.
The minute you meet Mark you know he is passionate about access to world-class healthcare. As the Group CEO, and a highly-regarded radiation therapist, Mark knows all too well the impact of cancer on patients, family and society. His leadership style is simple, nurture and challenge a team to deliver exceptional cancer care and grow the business to deliver that care for as many people as possible.
Since taking the reins in 2015, Mark has delivered a robust growth profile. In this time the Group has expanded into China and Singapore, with a significant South-East Asia reach, delivered a 50% increase in their radiation oncology footprint and driven acquisition in the chemotherapy compounding space to deliver one of Australia’s largest oncology manufacturers. Before this Mark led the Radiation Oncology Centres [ROC] team, including the successful acquisition of ROI and Oceania into the radiation oncology business.
Mark was a State Finalist for the Australian Institute of Management [AIM] Queensland Manager of the Year in 2014 and regional winner of the AIM Excellence Award 2015. He has a Master of Business Administration from Deakin University and is a Fellow of both the AIM and the Australian Institute of Radiography [AIR].
As the driving force behind Epic Group, including Epic Pharmacy and Epic Good Foundation, Cathie brings a passion for innovation to her role as Digital Advisor to the Board. As a significant contributor to Icon Group’s evolution and the depth of the business, Cathie intimately understands the operational challenges and opportunities facing the Group.
A tech geek at heart, Cathie has always believed in the role digital solutions have to play in the delivery of exceptional healthcare. It is this commitment that saw her found Epic Digital, a business focused on technology solutions that connect healthcare professionals with their patients, improving access to information, facilitating work flows and empowering patients to actively manage their health. Now part of Icon Group, Epic Digital is bridging the gap between the paper-based industry we know today and the digital future of tomorrow.
Cathie currently sits as on the Board of Assured Digital Group as a Director, the United Kingdom’s leading provider of digital infrastructure and information governance for sovereign data assets, and is the Chair of Flamingo Customer Experience Inc., an innovative software-as-a-service (SaaS) company developing customer experience automation platforms designed for selling complex financial products online. She has been recipient of several industry awards and honours including: induction into the Australian Businesswomen’s Hall of Fame in 2015, named one of the Top 100 Women of Influence by the Australian Financial Review in 2013, winner of the National Telstra Business Women’s Award in 2011, and recognised by Monash University with a Distinguished Alumni Award for Professional Achievement in 2012.
Cathie’s fascination in breaking new ground saw her invited to be part of the original Google Glass Explorer program and is one of Virgin Galactic’s future astronauts. She eagerly awaits the opportunity to travel into space and see the world from a very different perspective.
Marcus founded and manages QIC’s private equity program of $5.0bn AUM globally in funds, co‐investments, directs and direct secondary fund interests. He is at the forefront of a new private equity investment model reflected in a 2015 paper co-authored by Josh Lerner and Hugh MacArthur: The Next Generation Private Equity Investor. QIC’s Icon Group investment fits into a focused strategy of investing in growing business in attractive sectors in Australia and linking those business to other markets, especially China.
Prior to founding QIC’s program in 2005, Marcus was Chief Executive, North America, Altius Associates Ltd, with US$27 billion (as of Q2 2015) under management or advice. He established Altius’ US operation in 2000 and participated in the global management, investment strategy and execution, and client acquisition. From 1996 to 2000 Marcus worked for the Virginia Retirement System (“VRS”), a US public pension plan with assets of US$62billion. Marcus founded its non‐US portfolio and then became Head of Private Equity.
From 1990 to 1995 he worked in the London office of the Bankers Trust Company where he structured a number of buy‐out financings and worked on corporate restructurings. Marcus is Chairman Emeritus of the Institutional Investors Roundtable, an international community of large, long‐term institutional investors seeking to collaborate on private market investment.
From the moment you meet David you know his integrity runs through every part of the Slade business. As CEO, his dedication to customers, commitment to patient care and vision has seen the company become a leading national provider of hospital and compounding pharmacy services.
His deep understanding of the healthcare industry not only underpins the 50-year-old Slade Pharmacy business, but has been integral to the evolution of Slade Health. Seeing an opportunity to evolve outside of pharmacy, David established Slade Health in 2012. He recently led the acquisition of Fresenius Kabi and McBeath Oncology Compounding, which makes Slade Health one of Australia’s largest chemotherapy compounders.
David is passionate about innovation and using technology to improve the operations of the business. He was the first in Australia to introduce robotic dispensing technology into hospital pharmacy, develop and deploy an online ordering system for chemotherapy and unique barcoding technology to support patient safety in hospitals.